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COMBINED ACTION OF 5-FLUOROURACIL AND OTHER
CYTOTOXIC AGENTS WITH CRYSTALLINE RIBONUCLEASE
ON MOUSE ASCITES TUMORS
M.D.,* ARTHUR W . WASE, Ph.D.,**
AND JULIO CARDENAS. M.D.***

STEPHEN PODOLSKY,

(With the technical assistance of Zinaida Lashischenko)
As Brachet" has emphasized for many years, cytoplasmic ribonucleic acid (RNA)
ii of fundamental importance to life and is now generally believed to be the blueprint
c template directly involved in the synthesis of the body's enzymes. The RNA
St Tiehow directs the correct number of Ihe specific amino acids into the proper
si |uence to form the protein chain or chains of the enzyme. It, in turn, is probably
CCiistructed according to directions from the nuclear desoxyribonucleic acid (DNA).
A hough some believe that DNA (location of genes) is capable of duplicating itself,
rii onuclease (RNase) treated protoplast cannot resynthesize DNA.' Roth* has detected
ar increase in desoxyribonuclease (DNase) activity in cells incubated with crystalline
R ase, suggesting a degradative function of the latter enzyme. Nucleolar RNA is
qt ntitatively greater in all malignant cells.' Taylor and Long* have noted up to 70
til es greater RNA content of Grade I I I ovarian and endometrial neoplastic nucleolar
CO :s as compared to Grade L
Migliarese' reported an increase in RNase activity associated with the growth
of :ertain tumors in man and animals. Other workers* have shown an elevation of
ser im RNase in 71% of patients with cirrhosis and 629c of leukemic patients, but
in only about 30% of patients with carcinoma or Hodgkins disease. It is of great
interest that ribonuclease has been reported to demonstrate strong anti-mitotic and
growth-inhibiting effects on sea urchin eggs,''* living amoebae," onion root tips,^*"'*
salamander eggs," cells in tissue culture" and cells synthesizing tobacco mosaic virus,"
as well as certain experimental tumors."'" There is even a report of RNase causing
a temporary remission in chronic myelogenous leukemia."
Perhaps the most significant finding has been made by Ledoux who found
that RNase was capable of producing regressions of spontaneous mammary tumors
in C3H mice," which are unusually refractory to chemotherapy. However, other
workers found the drug ineffective in these cases." For the past six or seven years
Ledoux has been emphasizing the importance of ribonuclease in tumor therapy.
He has received some criticism because of the well known heterogenous nature
of RNase, as well as the fact that the bovine pancreatic enzyme he worked with
has a much smaller molecular weight than intracellular RNase's.
•^Drugs used in this study were obtained as follows: 5-FluorouraciI was supplied by Dr. William
Wilson, formerly, Chief, Cancer Chermotherapy Section, Hahnemann Medical College and Hospital,
Philadelphia. Pa. Glucose-1-Phosphate hydrazine and Polyphosphate were prepared and supplied
by Dr. Cardenas. 9-B-D Psicofuranosyl adenine was supplied by Dr. James Lawson, Upjohn Co.,
Kalamazoo. Michigan.
Supported by USPHS-NIH Grant CY-4403.
•Junior Medical Student. Hahnemann Medical College. Philadelphia, Pa.. Present address: Rotating
Intern. Henry Ford Hospital.
^'•Associate Professor of Biological Chemistry, Hahnemann Medical College.
••Research Pathologist, Department of Biological Chemistry, Hahnemann Medical College.
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We have been extensively studying the action of RNase on experimental tumors.
This communication records the effects on Ehrlich ascites tumor of RNase in
combination with olher agents reported to have a cancer chemolherapeutit
effect. The drugs were: 5-Fluorouracil (5-FU);"^ Glucose-1-phosphate hydrazin»
(G-l-P-H);"" 9-B-D psicofuranosyl adenine (psicofuranine);"" or condensed poly
merized phosphate chains.""
These drugs were selecled for a variety of reasons. 5-FU is a fluorinate 1
uracil and a pyrimidine antagonist which is incorporated into ribonucleic acids. •
In man the drug's highest concentration is found in the RNA of tumors an 1
inleslinal mucosa." It can prevent thymine synthesis by inhibiting thymidine syi Ihetase" and blocks uracil phosphatase so lhat preformed uracil cannot be utilizi .1
in RNA synthesis.*" G-l-P-H demonstrates a cytotoxic action presumably because 'f
its hydrazine group. The melabolic itself has been reported to be taken \ p
selectively by lumor cells.*'" Psicofuranine was recently developed as an antibio'ic
effective against M. aureus and E. coli and produced by a strain of actinomyct tc
identified as Streptomyces fiygro.scopicus var. decoy icus.*^ 11 is unusual in that il is
an abnormal ribonucleoside in which the sugar moiety (6 carbon sugar with penL se
lactone linkage), rather than the heterocyclic base, has a structural defect. The
drug inhibits the formation of guanylic from xanthanilic acid.*' Polyphosphate cha ns
inhibit several enzyme systems in vitro by competitive inhibition or by sequestrating
cations (Ca-t-+ and Mg^ + )." They may interfere with high energy phosphate systems
in vivo.
MATERIALS AND METHODS
Sarcoma 37 ascites tumors were maintained in adult female Swiss white mice
averaging 25 grams in weight by weekly inoculation of 0.2 ml. of cell suspension.
After such intraperitoneal (I. P.) injection of fresh asciies fluid, Ihe mice regularly
develop large amounts of milky ascites (5-15 ml.) in 6-12 days and die in 10-15 days.
These transplantable cancers have 100% "lakes" and rarely show spontaneous
regressions.
The RNase used was 5x recrystallized bovine pancrealic ribonuclease purchased
from Sigma C hemical Company. The mice were separated into several small
groups (10 conlrols and 10 experimentals, each). All experimental animals received
2 mg. RNase (80 mg/kilo) LP. daily for a week after the tumor had been
established 24 hours (days 1-8). The other drugs were administered in a similar
manner on the same days as separate injections. 5-FU was only given on days
1-6. Polyphosphates were prepared by dehydration of mixtures of monosodium
and disodium orthophosphate.** The maximal chain length was 67 phosphorus atoms.
Doses used were:
5-FU

0.5 mg/day

( 20 mg/kilo)

G-l-P-H

2.0 mg/day

( 80 mg/kilo)

psicofuranine

8.0 mg/day

(320 mg/kilo)

polyphosphate

1.0 mg/day

( 40 mg/kilo)
5S4
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All drugs were administered Ihrough a Swinney filler adapter to assure sterility.
/ Itibiotics were not used. Diet was Purina Laboratory Chow and tap water supplied
a libitum. The mice were maintained in air conditioned quarters (74°F).
RESULTS
In previous studies.***' we reported lhal 4-5 mg, crystalline RNase (Sigma)
gl en intraperitoneally daily 24 hours afler an ascites lumor was eslablished, prolo ged the survival time by a faclor of two. While the eff eel of a 2 mg. dose was
Vti iable in this respect, it nevertheless produced the same marked alteration in 8
d. tumor cytology seen with Ihe larger doses. One mg. doses had no effect.
A! hough combinations of tolal body x-irradiaiion plus LP. RNase (i.e., 2 mg. RNase
dii y plus 600r, day 2) seemed to have a synergistic effect in lhal survival lime
w; further prolonged, the lumor lolal packed cell volume was not inhibited to
lh< degree seen with 4-5 mg, RNase alone. A finding of perhaps grealer significance is
an appareni radiation protective effect of the enzyme. Mice which had received
do s of ionizing radiation which were 100*?r lethal to Ihe conlrols, lived either
lor, enough to die from their transplanted cancer, or even longer.
Although there was quite a bit of variation in different trials using 2 mg.
RN SC alone, the average survival time ol these animals in the various groups was
18 days (conlrols = 13.6 days). The results in the combination therapies are
shown in Table I. Ribonuclease plus 5-FU gave the most interesting findings, with
a p olongalion of survival period lo 2.5 times control (Fig. I ) . Total body weight
cha: ges, which are felt to reflect tumor growih, are shown for the controls and
for rhis group in Figs. 2 and 3.
There was some weight loss at these doses, but no deaths due to 5-FU
toxicity. When iherapy was stopped after the first week the weighls relurned to
Table I
SUMMARY OF COMBINATION THERAPY EFFECTS. 10 MICE IN EACH CONTROL
AND EXPERIMENTAL GROUP. (DOSES: RNase. 2 mg/day; 5-FU. 0,5 mg; G-I-P-H. 2 mg;
psicofuranine. 8 mg; polyphosphate. I mg)
Therapy
(Daily injections, Days 1-8)

Average Survival Time
(Treated/Conlrol)

Average Weight
Change/Day ( T / C )

Ribonuclease
alone

18,1/13.6 days

-^0,I5/-f-().74 g

5-FIuorouracil
4- RNase

32.5/13,4

-O.OI/m79

Glucose-1 -Phosphate
Hydrazine
+ RNase

20.2/13.3

+0.31/+0.83

Psicofuranine
-1- RNase

16,5/13.9

-I-0.39/+0.8I

Polyphosphate
-h RNase

14,5/13,6

-f-0.71/ + 0,91
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Figure 2
Average weight gain in control mice with ascites tumor.
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Figure 1
Prolongation of survival time
by intraperitoneal therapy with
ribonuclease plus 5-fluorouracil.
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Figure 3
Average weight change in tumor-bearing mice treated wilh RNase
plus 5-FU.

Figure 4
Control mouse (right) and one with identical tumor transplant, but treated with 2 mg. RNase pl^
0.5 mg. 5-FU. daily. (13 days after tumor inoculation.)
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p -treatment levels and ihereafler increased very litlle. Half of these animals
si )wed no sign of asciies lumor or solid lumor. Some of ihese animals were alive
6 ' weeks after tumor transplantation, before starting to show some emaciation
ai I succumbing lo solid abdominal wall and peritoneal malignancies. The other
5( f had a striking generalized carcinomatosis that was first seen at the Ihird
w k in sacrificed animals. There were numerous discrete masses of tumor infiltr ng the peritoneal tissues, especially the omentum and epiploons, as well as
Ih chain of ganglia and lymph nodes. Parenchymatous organs such as the kidneys
ar liver were also oflen involved by single or multiple whitish gray nodules of
a ibbery consistency and a small cystic surface on cul seclion. Cells were similar

r

Figure 5a

Figure 5b

Typ: \\ smear from a malignant ascites tumor.

Phase photomicrograph of a control smear,
showing several cells in active division. (Courtesy of Dr. Jens Christensen)

Figure 5c
1280 X enlargement of control smear. Several erythrocytes
are also seen, Papanicalaou stain, (Courtesy of Dr. Irena
Kowprowski)

to those of the original inoculum. Supra-diaphragmatic viscera showed a similar
picture, as did lymph nodes (cervical, mediastinal and inguinal). Occasionally
iaundice was seen when tumor involved lhe biliary tree. Several new solid tumors
*ere detected in the subcutaneous tissues of the back.
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Nothing unusual was noted with the other drugs, except that glucose-1-phosphate
hydrazine had a similar or slightly synergistic effect with RNase. Psicofuranine
or polyphosphate had no effect or inhibited RNase action.
Inoculation of experimental animals wilh malignant cells in which RNA conlen
has been reduced by storage at 4 X is much less effective in producing tumo
"lakes" than inoculation wilh fresh cells.*' Simultaneous adminislration of RN^v
causes an increased number of tumors.*' When normal rat liver cells are treateJ
with RNA from malignant liver cells and then inoculated I.P. into rats, 20**

Figure 6a
Smear
5-FU.
usual.
RNase

Figure 6b

from animal treated with RNase plus
Many of the cells are smaller than
Effect is similar to that seen with
alone.

Smear from animal treated with RNase plus
polyphosphate. No great morphological alteration.

develop tumors whereas none did when normal liver RNA was added." Howes er.
Niu*'" found RNA effect to be relaled to dose. In physiologic concentration il
could produce differentiation of young urodele gastrula, while very large doses
actually prevenled furlher growth of lhe embryo or transplantalion I.M. of ascites
cells (incubated with normal mouse liver RNA)."

Figure 7

Figure 8
Animal sacrificed 28 days after tumor inoculation, treated with RNase plus 5-FU. showing
large solid tumor filling lower abdomen and
matting together much of thc viscera. This
tumor, as well as all of the animal's subcutaneous tissues and sclerae, was intensely ictenc

Animal sacrificed 28 days after Sarcoma 37
injection, and treated for one week with RNase
and 5-FU. Note minimal amount of viscous
ascites. Spleen is riddled with small solid tumors and several were present in the mesentery.
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DISCUSSION
DeCarvalho and Rand** have reported a modification of rat Novikoff hepatoma
g )wth by treating the cells with RNA from other hepatoma cells prior to transp intation. A much more widely disseminated neoplastic picture with unusual
V lespread metastases was seen, although prior treatment of the controls with
n< rmal rat liver RNA caused no such alteration. Despite the more malignant
gl 'Wth pattern of the former, some regressions were seen, although none were
st n with the controls. Their description is quite similar lo the RNase -j- 5-FU
et :ct on some mouse ascites tumors. While it is conceivable that one or two of
th solid tumors may have developed spontaneously, it is highly doubtful that all
ot hem did.
Although RNase and G-l-P-H have a more beneficial effect when used together,
il s not an additive one. While we feel that the action is due to a cytotoxic
el ct of the hydrazide, it is quite possible that the compound is a specific antagonist.
Tl IS, D-glucosamine, a competitive inhibitor of glucose for hexokinase, inhibits both
Sa coma 37 and human epidermoid carcinoma in tissue culture."^
Exten.sive studies with polyphosphates on solid and ascites mouse tumors showed
Ih. they were ineffective in these animals, perhaps due to a species specific
en. me. The loss of the usual RNase effect when the drugs were used together
m;i V have been due to inactivation of the enzyme by phosphorylation which occurs
even with a single phosphorus atom." There has been at least one definite temporary

Figure 9

Figure 10

Autopsy 35 days after tumor transplant and
Ireatment (RNase plus 5-FU), showing solid
mesenteric tumor with isolated hepatoma. Latter has a smaller neoplasm near it.

This animal represented another clinical "cure"
but showed a small amount of bright yellow
asciies plus multiple liver metastases when it
died. A solitary left renal tumor was also
present.

remission, both clinically and hemotologically, in a patient with leukemia on polyphosphate." A tendency to hypocalcemia and even tetany is a significant toxic effect.
At Henry Ford Hospital three terminal cancer patients were given polyphosphate
in daily intravenous drips for 60 minutes at doses up lo 600 mg. (8 mg/kilo)."
No effect, including any change in serum calcium, was seen.
We were able to confirm the lack of chemotherapeutic action of psicofuranine
on the Ehrlich tumor. When used with RNase, the biological effect was similar
to that obtained only with the latter treatment. Because of its unique structure,
psicofuranine has had extensive clinical trials, but antitumor activity at non-toxic
58^
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doses was negligible. An unusual syndrome produced is polyserositis, especial y
pericarditis.**"" Nine of 12 patienls at this institution developed the fullblown pictu e
of fever, mental confusion, moderate leucocytosis and severe chest pain with audib e
pericardial friction rub." Symptoms subsided when the drug was discontinued ai d
returned upon readminisiration. In some the picture resembled the Periodic Disci^c
originally described by Reimann,"" laler referred to as Familial Medilerranc in
Fever*' and recently renamed by Nixon and Priest*' ** as Familial Recurri ig
Polyserositis.
Ledoux" estimated that Ihe Armour beef pancreas RNase he used in retard ig
C3H mice spontaneous mammary lumor growth contained 25-30% of fully act ve

Figure I la
28 day tumor treated with RNase plus 5-FU
for one week after tumor transplant. Solid
lumor in lower abdomen.

Figure 11 b

Mass uncovered. It involves the ventral peritoneum. No ascites was present.

enzyme and 70-75'^t of inactive low molecular weight RNase. There was an
impression lhat the inactive portion could inhibit the active one. He found lhat
two intraperitoneal injections (days 7 and 8) of 2 mg. Armour RNase purified
by chromatography (peak "D", Ihe largest peak) plus 0.1 mg. nucleotide almost
tripled the survival time of a group of ascites tumors." Other doses when given
without nucleotide or even 10-20 mg. doses of unpurified enzyme, had a less
beneficial effect. Extensive studies"***' have led him to believe that the cancerocidal

Figure lie
The tumor dissected out. Above is the animal's
spleen, which was larger than normal.
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etfect of RNase is due to the rapid synthesis of a new and abnormal cellular RNA,
I ch in pyrimidine bases, which somehow initiates cellular alterations and a steady
d crease in RNA.
RNase is frequently reported to be present in the cytoplasmic mitochondria.*'
R cent workers have shown that it is actually located in cytoplasmic particles called
"i sosomes",'* which may contaminate mitochondral fractions. It has been shown
th t rat liver RNase has two peaks of activity, one at acid pH and another at
al aline pH."" Roth has noted that an RNase inhibitor is normally present in the
ra liver,'' and has recently described a third rat liver RNase which is bound to
th ^ inhibitor and found in the supernatant fraction.'* The optimum activity of the
er yme occurs at the same pH, whether in solution or adsorbed to a surface."
An important report made earlier this year concerns a ribonuclease inhibitor
wl ch has been isolated from Ehrlich ascites tumor cells." This has been shown to
ini ibit bovine pancreatic RNase and could possibly play a role in these chemoth. apeutic trials. Bivalent ions such as Mg+-i-, Mn++ and Cu-^-^ all inhibit RNase
alt ck on rat microsomal ribonucleoprotein." Several polyionic compounds, especially
po methacrylic acid, reverse RNase inhibition of protein synthesis." Many workers
ha^ * uncoiled the chain of 124 amino acids that make up RNase by breaking
dis Ifide bridges but not the chain itself, so that the enzyme is inactivated. This
pre ess is reversible and thought to be a mere "uncoiling" rather than true
der Iiuration because reactivation of RNase can be brought about by proper conditions. Thus the compound refolds under the influence of RNA, if there are polyvakni anions in the substrate, even in the presence of strong agents like 8 M urea
or 1 to 3 M solutions of guanidium ions.'* Activity of reduced and modified RNase
is also restored by the presence of molecular oxygen and suitable alkalinity
SUMMARY
Ribonucleic acid is directly involved in the synthesis of most of the important
enz\mes and proteins, under physiological conditions. There is gorwing opinion that
the riddle of cancer may lie in some abnormality of nucleoprotein metabolism,
especially of RNA. Important work has been performed and frequently reported
by Ledoux on ribonuclease action against various experimental tumors. Wc have
confirmed some of these studies and extended the work. Other workers have had
difficulty in reproducing his results, although Ledoux himself has reported a variation
of biological effect with different sources and lots of crystalline bovine pancreatic
RNase.
In the present experiments crystalline RNase was used in combination wilh
several other drugs in the mouse Sarcoma 37 ascites tumor. Two of the agents,
glucose-1-phosphate hydrazine and polyphosphate, were prepared in our own laboratories. The other drugs were an abnormal nucleoside, 9-B-D psicofuranosyl
adenine, and 5-fluorouracil. Intraperitoneal injection of 2 mg. RNase daily (days 1-8)
*nd 0.5 mg. 5-FU daily (days 1-6) resulted in a prolongation of average survival
^'tne 2.5 times that of the controls (32.5 compared to 13.4 days). Furthermore,
steady weight gain as a manifestation of tumor growth was not seen in the treated
''Jice. Half of them never developed any ascites tumor but died within six weeks
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with large solid abdominal wall and peritoneal lumors. The olher 50% had ; n
unusual widespread carcinomatosis that was first delected three weeks after origin d
transplant. Solid tumor involved all of thc peritoneal and omental tissues, as w II
as liver, kidneys, heart, cervical, mediastinal and inguinal lymph nodes, and sii>
cutaneous lissues of the back. Jaundice was sometimes seen. Peritoneal smear ix
days afler lumor inoculation showed numerous small round cells wilh minir al
cytoplasm and some nuclear pycnosis. Occasional typical ascites tumor cells were se n.
Glucose-1-phosphate hydrazine plus RNase produced a survival time of 2'L2
days, which was slightly greater lhan with the enzyme alone. Psicofuranine : ad
no additive effect and polyphosphate seemed to reduce the usual RNase eff cL
Ascitic smears from an 8 day animal of the latter group failed to show any unu^ al
cytological changes.
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